Parnell Pharmaceuticals Holdings Ltd (PARNF)
Parnell Pharmaceuticals Holdings Ltd operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Alexandria, NSW, AU. The stock last traded at $0.08, down 51.52% on the session, giving a market capitalisation of $1.7M. On trailing twelve-month figures it carries a trailing P/E of -2.32, a net margin of -4.2%. Its beta of 626.88 implies it has historically moved more than the broad market.
Parnell Pharmaceuticals Holdings Ltd is a well-established biopharmaceutical company that focuses on the entire lifecycle of animal health solutions, from development and manufacturing to global distribution. The company organizes its operations into four distinct business units: Companion Animal, Production Animal - U.S., Production Animal - Rest of World, and Manufacturing Operations. Its diverse product portfolio includes key offerings like estroPLAN and GONAbreed, which are hormone-based treatments designed to enhance reproductive performance in cattle. For addressing osteoarthritis, Parnell provides Zydax, a therapeutic injection for dogs and horses, as well as Glyde, a nutraceutical supplement. The company further offers Parnell PROcept, a protocol that incorporates an additional estroPLAN injection. Beyond pharmaceutical products, Parnell also developed mySYNCH, a digital platform crafted to assist veterinarians and livestock producers in streamlining reproduction management and improving economic yields. Parnell Pharmaceuticals Holdings Ltd was founded in 2009 and maintains its corporate headquarters in Alexandria, Australia.
Parnell Pharmaceuticals Holdings Ltd is most often compared with the following Healthcare names: